DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Lung Cancer
  4. Research Highlights/News
  5. 2023 Lung Cancer Research Program

Lung Cancer

NEWS RELEASE

Released: March 22, 2023

Department of Defense (DOD)
Congressionally Directed Medical Research Programs (CDMRP)
Lung Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)

The FY23 Defense Appropriations Act provides funding for the Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunity. This pre-announcement should not be construed as an obligation by the government. The FY23 LCRP funding opportunity announcement for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcement is released.

Applications submitted to the FY23 LCRP must address one or more of the following Areas of Emphasis: 

  • Biology and Etiology
    • Understand the molecular mechanisms of initiation and progression to lung cancer.
    • Understand contributors to lung cancer development other than tobacco.
  • Prevention
    • Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries.
    • Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
  • Detection, Diagnosis, and Surveillance
    • Improve approaches to screening and early detection of lung cancer.
    • Identify strategies for prompt detection and/or characterization of progressive disease.
  • Treatment and Prognosis
    • Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
    • Develop or optimize biomarkers to assist with therapeutic decision-making.
    • Enhance the treatment and understanding of brain metastases in lung cancer.
  • Health Outcomes and Survivorship
    • Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) with respect to the impact of comorbidities on patient care and also, more broadly, in respect to their effects on patients and their quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects.
  • Disparities
    • Advance equity and reduce lung cancer disparities among underserved and underrepresented populations.

Relevance to Military Health: The LCRP seeks to support research that is relevant to the health care needs of military Service Members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the Defense Health Program and FY23 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health: 

  • Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research.
  • Collaboration with DOD or Department of Veterans Affairs investigators.
  • Explanation of how the project addresses an aspect of lung cancer that has a direct relevance or is unique to the military, Veterans, other military health system beneficiaries, or family readiness of Service Members, including environmental exposures other than tobacco.

Award Mechanism Eligibility Key Mechanism Elements Funding
Patient-Centered Outcomes and Survivorship Award

NEW!!!		 Independent investigator with a faculty-level appointment (or equivalent)
  • Letter of Intent is required. An invitation to submit a full application is not required.

  • Supports high-reward studies that span the spectrum of behavioral health science, survivorship and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions and examining the physical, psychological, social and economic effects of lung cancer.

  • Must address at least one area of emphasis in the Disparities or Health Outcomes/Survivorship categories.

  • Preliminary data required.

  • Pilot clinical trials are allowed.

  • Relevance to military health is strongly encouraged.
  • Maximum funding of $600,000 in direct costs (plus indirect costs).

  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using Assistance Listing Number (ALN, formerly CFDA) 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).


Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Wednesday, March 22, 2023